DaVita (NYSE:DVA) Stock Price Down 3.4%

DaVita Inc. (NYSE:DVA)’s stock price dropped 3.4% during trading on Friday . The company traded as low as $137.63 and last traded at $137.67. Approximately 260,304 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 837,194 shares. The stock had previously closed at $142.50.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Barclays raised their price objective on shares of DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a report on Monday, May 6th. Truist Financial upped their price objective on DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, May 15th. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Finally, TD Cowen lifted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $146.00.

DaVita Stock Performance

The firm has a market cap of $12.10 billion, a P/E ratio of 15.68, a price-to-earnings-growth ratio of 1.10 and a beta of 0.87. The stock’s 50-day moving average price is $140.68 and its 200 day moving average price is $131.01. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company had revenue of $3.07 billion during the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter last year, the company earned $1.58 EPS. DaVita’s revenue for the quarter was up 6.9% compared to the same quarter last year. As a group, equities analysts predict that DaVita Inc. will post 9.62 EPS for the current year.

Insider Activity at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the transaction, the director now directly owns 10,954 shares in the company, valued at approximately $1,520,524.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DVA. Blue Trust Inc. raised its stake in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares during the period. Newbridge Financial Services Group Inc. bought a new position in shares of DaVita in the fourth quarter valued at about $30,000. Principal Securities Inc. acquired a new stake in shares of DaVita during the 4th quarter worth about $37,000. Family Firm Inc. bought a new stake in shares of DaVita during the 2nd quarter worth about $43,000. Finally, Versant Capital Management Inc grew its stake in DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after buying an additional 155 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.